Cost-effectiveness of DNA Stool Testing to Screen for Colorectal Cancer. Technology Assessment Program

摘要

Despite recent declines in both incidence and mortality, colorectal cancer (CRC) is the second most common cause of cancer death in the United States. CRC screening reduced CRC mortality by 15-33% in randomized controlled trials with Hemoccult II fecal occult blood tests (FOBTs). Novel CRC screening technologies, such as the DNA stool test have been developed but need to be evaluated in terms of their comparability of diagnostic performance (sensitivity and specificity) in detecting adenomatous polyps and CRC, acceptability to patients, and test-related complications and costs. Accordingly, we conducted a cost-effectiveness analysis of the DNA stool test and other currently recommended CRC screening strategies.